Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective.

Singh D, D'Urzo AD, Donohue JF, Kerwin EM.

Respir Res. 2019 Jul 8;20(1):141. doi: 10.1186/s12931-019-1108-9. Review.

2.

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.

D'Urzo AD, Singh D, Donohue JF, Chapman KR.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619850725. doi: 10.1177/1753466619850725.

3.

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.

D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 26;14:479-491. doi: 10.2147/COPD.S185502. eCollection 2019.

4.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

5.

Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.

D'Urzo A, Bader G, Shen S, Goyal P, Altman P.

NPJ Prim Care Respir Med. 2018 May 24;28(1):18. doi: 10.1038/s41533-018-0084-8.

6.

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.

D'Urzo AD, Kardos P, Wiseman R.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 4;13:1089-1104. doi: 10.2147/COPD.S160577. eCollection 2018. Review.

7.

FEV1 reversibility for asthma diagnosis: a critical evaluation.

Ye Q, Liao A, D'Urzo A.

Expert Rev Respir Med. 2018 Apr;12(4):265-267. doi: 10.1080/17476348.2018.1439741. Epub 2018 Feb 17. No abstract available.

PMID:
29426266
8.

Difficultés liées au diagnostic de déficit en α1-antitrypsine en soins de première ligne.

Ye Q, D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):e655-e658. French. No abstract available.

PMID:
28661883
Free Article
9.

Challenge of α1-antitrypsin deficiency diagnosis in primary care.

Ye Q, D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):899-901. No abstract available.

10.

Response.

D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):875-877. No abstract available.

11.

Why primary care guidelines are not prepared by family physicians.

D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):874. No abstract available.

12.

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.

Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.

Respir Res. 2017 May 30;18(1):106. doi: 10.1186/s12931-017-0583-0.

13.
14.

Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors.

De Simone A, Fiori J, Naldi M, D'Urzo A, Tumiatti V, Milelli A, Andrisano V.

J Pharm Biomed Anal. 2017 Sep 10;144:159-166. doi: 10.1016/j.jpba.2017.02.036. Epub 2017 Feb 27.

PMID:
28268049
15.

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.

D'Urzo A, Singh D, Garcia Gil E.

NPJ Prim Care Respir Med. 2017 Feb 24;27(1):13. doi: 10.1038/s41533-016-0009-3.

16.

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.

Miravitlles M, D'Urzo A, Singh D, Koblizek V.

Respir Res. 2016 Sep 10;17(1):112. doi: 10.1186/s12931-016-0425-5. Review.

17.

Site-specific quantification of lysine acetylation in the N-terminal tail of histone H4 using a double-labelling, targeted UHPLC MS/MS approach.

D'Urzo A, Boichenko AP, van den Bosch T, Hermans J, Dekker F, Andrisano V, Bischoff R.

Anal Bioanal Chem. 2016 May;408(13):3547-53. doi: 10.1007/s00216-016-9431-1. Epub 2016 Mar 11.

18.

Direct determination of GSK-3β activity and inhibition by UHPLC-UV-vis diode arrays detector (DAD).

D'Urzo A, De Simone A, Fiori J, Naldi M, Milelli A, Andrisano V.

J Pharm Biomed Anal. 2016 May 30;124:104-111. doi: 10.1016/j.jpba.2016.02.029. Epub 2016 Feb 23.

PMID:
26942334
19.

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.

D'Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D'Andrea P, Hu H, Goyal P, Altman P.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 11;10:1599-612. doi: 10.2147/COPD.S81266. eCollection 2015.

20.
21.

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.

D'Urzo A, Donohue JF, Kardos P, Miravitlles M, Price D.

Expert Opin Pharmacother. 2015;16(12):1845-60. doi: 10.1517/14656566.2015.1067682. Review.

22.

Differences in spirometry interpretation algorithms: influence on decision making among primary-care physicians.

He XO, D'Urzo A, Jugovic P, Jhirad R, Sehgal P, Lilly E.

NPJ Prim Care Respir Med. 2015 Mar 12;25:15008. doi: 10.1038/npjpcrm.2015.8.

23.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF; AUGMENT COPD study investigators.

Respir Res. 2014 Oct 14;15:123. doi: 10.1186/s12931-014-0123-0.

24.

Response.

D'Urzo AD, Abitbol L.

Can Fam Physician. 2015 Feb;61(2):127. No abstract available.

25.

Molecular basis for structural heterogeneity of an intrinsically disordered protein bound to a partner by combined ESI-IM-MS and modeling.

D'Urzo A, Konijnenberg A, Rossetti G, Habchi J, Li J, Carloni P, Sobott F, Longhi S, Grandori R.

J Am Soc Mass Spectrom. 2015 Mar;26(3):472-81. doi: 10.1007/s13361-014-1048-z. Epub 2014 Dec 16.

PMID:
25510932
26.

Fatal aortic dissection in a 37-year-old man: missed opportunity.

Abitbol L, D'Urzo A.

Can Fam Physician. 2014 Dec;60(12):1116-9. No abstract available.

27.

The conformational response to Zn(II) and Ni(II) binding of Sporosarcina pasteurii UreG, an intrinsically disordered GTPase.

D'Urzo A, Santambrogio C, Grandori R, Ciurli S, Zambelli B.

J Biol Inorg Chem. 2014 Dec;19(8):1341-54. doi: 10.1007/s00775-014-1191-9. Epub 2014 Sep 9.

PMID:
25200810
28.

The challenge of objective confirmation of asthma diagnosis in primary care.

Kaicker J, Dang W, D'Urzo A.

NPJ Prim Care Respir Med. 2014 Jul 24;24:14032. doi: 10.1038/npjpcrm.2014.32.

29.

Effectiveness of omalizumab in severe persistent asthma under real-life conditions.

D'Urzo AD, Wong J.

Can Fam Physician. 2014 Jul;60(7):643-5. No abstract available.

30.

New therapy for managing moderate to severe chronic obstructive pulmonary disease.

Chou A, D'Urzo AD.

Can Fam Physician. 2014 Apr;60(4):352-4. No abstract available.

31.

Interactions of ataxin-3 with its molecular partners in the protein machinery that sorts protein aggregates to the aggresome.

Bonanomi M, Mazzucchelli S, D'Urzo A, Nardini M, Konarev PV, Invernizzi G, Svergun DI, Vanoni M, Regonesi ME, Tortora P.

Int J Biochem Cell Biol. 2014 Jun;51:58-64. doi: 10.1016/j.biocel.2014.03.015. Epub 2014 Mar 28.

PMID:
24685680
32.

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.

Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P.

BMC Pulm Med. 2014 Jan 17;14:4. doi: 10.1186/1471-2466-14-4.

33.

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.

Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D.

Eur Respir J. 2014 Jun;43(6):1599-609. doi: 10.1183/09031936.00124013. Epub 2013 Oct 31.

34.

Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies.

D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P.

Curr Med Res Opin. 2014 Mar;30(3):493-508. doi: 10.1185/03007995.2013.858618. Epub 2013 Nov 19.

PMID:
24156566
35.

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD.

D'Urzo A.

Ther Clin Risk Manag. 2013;9:341-53. doi: 10.2147/TCRM.S30317. Epub 2013 Aug 19.

36.

Characterization of the genome of the dairy Lactobacillus helveticus bacteriophage {Phi}AQ113.

Zago M, Scaltriti E, Rossetti L, Guffanti A, Armiento A, Fornasari ME, Grolli S, Carminati D, Brini E, Pavan P, Felsani A, D'Urzo A, Moles A, Claude JB, Grandori R, Ramoni R, Giraffa G.

Appl Environ Microbiol. 2013 Aug;79(15):4712-8. doi: 10.1128/AEM.00620-13. Epub 2013 May 31.

37.

One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.

D'Urzo A, Kerwin E, Rennard S, He T, Gil EG, Caracta C.

COPD. 2013 Aug;10(4):500-10. doi: 10.3109/15412555.2013.791809. Epub 2013 May 16.

PMID:
23679347
38.

Extracting structural information from charge-state distributions of intrinsically disordered proteins by non-denaturing electrospray-ionization mass spectrometry.

Testa L, Brocca S, Santambrogio C, D'Urzo A, Habchi J, Longhi S, Uversky VN, Grandori R.

Intrinsically Disord Proteins. 2013 Apr 1;1(1):e25068. doi: 10.4161/idp.25068. eCollection 2013 Jan-Dec. Review.

39.
40.
41.

Four-year trial of tiotropium in chronic obstructive pulmonary disease.

D'Urzo AD, Jugovic P, Jhirad R, Bouchard J.

Can Fam Physician. 2012 Aug;58(8):848-9. No abstract available.

42.

Future of chronic obstructive pulmonary disease management.

D'Urzo A, Vogelmeier C.

Expert Rev Respir Med. 2012 Jun;6(3):285-99. doi: 10.1586/ers.12.20. Review.

PMID:
22788943
43.

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators.

Thorax. 2012 Sep;67(9):781-8. Epub 2012 Apr 27.

PMID:
22544891
44.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators.

COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.

PMID:
22320148
45.

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T.

Respir Res. 2011 Dec 7;12:156. doi: 10.1186/1465-9921-12-156.

46.

Limitations of a spirometry interpretation algorithm.

D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P.

Can Fam Physician. 2011 Oct;57(10):1153-6. No abstract available.

47.

New spirometry interpretation algorithm: Primary Care Respiratory Alliance of Canada approach.

D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P.

Can Fam Physician. 2011 Oct;57(10):1148-52. No abstract available.

48.

Spirometry interpretation in primary care.

D'Urzo AD.

Can Fam Physician. 2011 Oct;57(10):1122. No abstract available.

49.

Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: yes.

D'Urzo AD.

Can Fam Physician. 2011 Aug;57(8):870, 872, 874, 876; discussion e277, e279. English, French. No abstract available.

50.

Confirmation of asthma diagnosis in the community.

D'Urzo A.

Eur Respir J. 2011 Jan;37(1):221-2; author reply 223-4. doi: 10.1183/09031936.00136210. No abstract available.

Supplemental Content

Loading ...
Support Center